For the quarter ending 2025-09-30, MCRB had $2,259K increase in cash & cash equivalents over the period. $2,198K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 8,204 | 12,827 |
| Stock-based compensation expense | 2,482 | 5,159 |
| Depreciation and amortization expense | 1,044 | 2,135 |
| Non-cash operating lease cost | 2,125 | 4,109 |
| Gain on sale of vowst business, net of transaction costs | 0 | - |
| Amortization of debt issuance costs | 0 | 0 |
| Loss associated with extinguishment of debt | 0 | - |
| Loss on disposal of fixed assets | 0 | 0 |
| Impairment of long-lived assets | 0 | 0 |
| Change in fair value of warrant liabilities | 0 | 0 |
| Accounts receivable due from spn - related party | -456 | -1,186 |
| Accounts receivable | 351 | - |
| Prepaid expenses and other current and other non-current assets | -688 | 3,389 |
| Collaboration receivable - related party | 0 | 0 |
| Inventories | 0 | 0 |
| Deferred income - related party | 0 | 0 |
| Accounts payable | -515 | -1,887 |
| Accrued liabilities due to spn - related party | 9,003 | 4,297 |
| Operating lease liabilities | -2,181 | -4,206 |
| Accrued expenses and other current and long-term liabilities | 633 | -4,794 |
| Net cash provided by (used in) operating activities | 2,206 | 13,621 |
| Purchases of property and equipment | 8 | 215 |
| Sales of restricted investments | 0 | 0 |
| Proceeds from sale of vowst business | 0 | - |
| Net cash (used in) provided by investing activities | -8 | -215 |
| Proceeds from at the market equity offering, net of issuance costs | 0 | 996 |
| Proceeds from exercise of stock options | 15 | - |
| Proceeds from securities purchase agreement - related party | 0 | - |
| Issuance of common stock under espp | 46 | 184 |
| Repayment of notes payable | 0 | - |
| Net cash provided by (used in) financing activities | 61 | 1,180 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 2,259 | 14,586 |
| Cash and cash equivalents at beginning of period | 39,461 | - |
| Cash and cash equivalents at end of period | 56,306 | - |
Seres Therapeutics, Inc. (MCRB)
Seres Therapeutics, Inc. (MCRB)